A New Ozempic Pill? Roche Shakes Up the Weight Loss Drug Market With Promising Results: See The Data

The race to develop effective weight loss medications has intensified in recent years, driven by increasing demand and a growing number of competitors eager to capture market share. The competition is fierce, as you may have already seen with popular brands like Ozempic. And now, medical company Roche has emerged as a significant player with its recent announcement of promising early-stage trial data for its new obesity drug candidate, CT-996. The Swiss pharmaceutical giant's success has led to notable market reactions, affecting major competitors like Novo Nordisk and Eli Lilly. Here's what to know about the trial data.

What were the Roche weight loss drug trial results?

In an announcement Wednesday , Roche's experimental once-daily pill, CT-996, demonstrated a placebo-adjusted average weight loss of 6.1% within four weeks among obese patients without Type 2 diabetes during its Phase I trial. This positive outcome offers a potential alternative to injectable weight loss treatments, which many patients find less appealing.

Roche's Chief Medical Officer, Levi Garraway, expressed optimism about the clinical results. “We are pleased to see the clinically meaningful weight loss in people treated with our oral GLP-1 therapy CT-996, which could eventually help patients address both chronic weight management and glycemic control indications,” he shared in a statement.

What impact did the Roche weight loss drug trial have?

The announcement of Roche's promising trial data had immediate repercussions in the stock market. Shares of Novo Nordisk, the maker of Wegovy, fell by 4%, while Eli Lilly, known for its Zepbound drug, saw a 3% decline. Danish biotech company Zealand Pharma, also developing its own obesity treatment, experienced an 8.4% drop in share value. In contrast, Roche's shares surged by 5.8% following the news, underscoring investor confidence in the new drug's potential.

Before Roche, the market was dominated by Novo Nordisk and Eli Lilly. Novo Nordisk, with its blockbuster drugs Ozempic and Wegovy, and Eli Lilly, with its Zepbound treatment, were leading the field with their highly effective GLP-1 receptor agonists.

Health

Could Ozempic and Other Weight Loss Drugs Reduce Bone Density? New Study Shows What Can Help

A June study published in the journal JAMA network looks at bone mineral density concerns

How was the Roche weight loss drug trial supported?

Roche's advancements in obesity treatment were supported by its acquisition of Carmot Therapeutics, an anti-obesity drug developer, completed in January. This move has made Roche a formidable contender in the weight loss medication market. In addition to CT-996, Roche released promising early-stage data for another drug candidate, CT-388, in May.

The history of weight loss drugs

The weight loss drug sector dates back several decades, with early treatments often focusing on appetite suppression and metabolic enhancement. However, these initial efforts resulted in negative side effects and limited efficacy. In recent years, the introduction of injectable GLP-1 agonists, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, marked a significant breakthrough. These drugs work by mimicking hormones that regulate appetite and blood sugar levels, leading to substantial weight loss and improved metabolic health.

Health

Does Ozempic Make You Tired? Docs Share the Surprising Reason + Easy Energy Boosters

See the timing tweak that fights fatigue and crushes cravings

What this means for you if you want to use a weight loss drug

Despite the promising early results, Roche Pharmaceuticals CEO Teresa Graham has cautioned that it may take several years before these oral obesity treatments become widely available.

Nonetheless, an effective oral weight loss medication, like Roche’s CT-996, could be a game-changer for those seeking easier treatment options. A daily pill eliminates the need for injections, which may lead to better adherence to the treatment regimen and potentially improved outcomes. However, it’s important to consider the potential side effects and consult with a healthcare provider to determine the best treatment plan for your needs. Staying informed about the latest research advancements can help you make more informed decisions for your health journey.

More on semaglutide and weight loss:

Dietitians Reveal the 3 Types of Foods You Should Avoid While on Semaglutide to Speed Weight Loss

MD: You Can Get the Weight Loss Benefits of Ozempic *Without* the Side Effects

Little-Known Ozempic Side Effect Is Worse for Women over 50: MDs Explain & Advise